Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Moksi · 1 trial · 1 indication
maximum plasma concentration of Moxifloxacin
Area under plasma concentration time curve from zero to time of the last measurable concentration
area under the plasma concentration-time curve from zero to infinity.
| Arm | Type | Description |
|---|---|---|
| Moksi® 400mg Tablet of Abbott | EXPERIMENTAL | Healthy subjects were orally administered a single dose of Moksi® 400mg Tablet (Moxifloxacin) under fasting condition |
| Avelox® 400mg Tablet of Bayer | ACTIVE_COMPARATOR | Healthy subjects were orally administered a single dose of Avelox® 400mg Tablet (Moxifloxacin) under fasting condition. |
| Name | Type | Description |
|---|---|---|
| Moksi® 400mg Tablet | DRUG | Single dose of Moxifloxacin 400 mg Tablet was administered after a 10-hour overnight fast. |
| Drug: Avelox® 400Mg Tablet | DRUG | Single dose of Moxifloxacin 400 mg Tablet was administered after a 10-hour overnight fast. |
Inclusion Criteria: 1. Healthy male volunteers aged 18 to 55 years inclusive. 2. Subjects with a body mass index from 18.5 to 30 kg/m2 (both inclusive). 3. Subjects who are healthy as determined by routine physical examination,including vital sign monitoring (ie, blood pressure, heart rate,and temp...
Moksi is an investigational small molecule developed by Abbott Laboratories (ticker ABT). It is also known as Moksi 400mg Tablet. The program is in Phase 1 clinical development, and the specific therapeutic indication has not been disclosed.
Moksi is developed by Abbott Laboratories, which trades under the ticker ABT. Abbott is the sponsor of the clinical program for Moksi, including the completed Phase 1 bioequivalence study conducted in Pakistan.
Moksi is in Phase 1 clinical development. One Phase 1 trial has been completed and no trials are currently active. The program has not been approved by the FDA and remains investigational.
Moksi has been evaluated in one completed Phase 1 trial, NCT05307614. This was a bioequivalence study of Moksi 400mg Tablet and Avelox 400mg Tablet (moxifloxacin) under fasting conditions in healthy adult Pakistani subjects, enrolling 38 male participants.